This is a working overview of prohibited substance, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming is inconsistent across suppliers and publications |
| Reported sequence | Ac-LKKTETQ | Corresponds to residues 17-23 of the parent protein |
| Frequently cited registry number | 77591-33-4 | Associated with full-length thymosin beta-4 rather than the fragment |
| Common supplied form | Freeze-dried solid | Often presented as an acetate or trifluoroacetate salt |
| Regulatory treatment | Varies by country | Frequently handled as a research chemical; not broadly approved as a therapeutic |
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Floating villi float freely in the intervillous space. They exhibit a bi-layered epithelium consisting of cytotrophoblasts with overlaying syncytium (syncytiotrophoblast). Anchoring (stem) villi stabilize the mechanical integrity of the placental-maternal interface.
Infections can occur anywhere from December to June, and can take place throughout any point during and following harvesting. Transmission can occur mechanically, or via conidial dispersal in water or air to fruit surfaces. Conidia often reside within soil, but can also be found in the air of contaminated storage spaces. Being a wound pathogen, fruit injuries are required for successful fruit infections, with much of these injuries occurring due to improper handling during the harvesting process. Injuries can also be caused by other events such as frost and insect bites, and can be as minor as damage to fruit skin oil glands. Fallen fruit can also be susceptible to P. digitatum infections, as has been noted in Israel, where P. digitatum infects fallen fruit more than P. italicum. Pathogenicity of P. digitatum is suggested to rely on the acidification of the infected fruit. During fruit decay, this species has been observed to make citric acid and gluconic acid and sequester ammonium ions into its cytoplasm. The low pH may aid in the regulation of various gene-encoded pathogenic factors such as polygalactouronases. In addition, P. digitatum has been observed to modify plant defense mechanisms, including phenylalanine ammonia lyase activity, in the citrus fruits it infects. Modifications to the disease cycle of P. digitatum have been induced experimentally. For example, P. digitatum has been observed to cause infection in unwounded fruits through mechanical transmission, although a higher infection dose was required in such instances.
=== Further === Burnside College ESPA College Gateshead College Harton Academy and Sixth Form Newcastle College Newcastle Sixth Form College Tyne Metropolitan College South Tyneside College Sunderland College
The main function of trypanothione synthase is to use the free energy generated from ATP hydrolysis to conjugate glutathione and spermidine to form the intermediate of glutathionylspermidine and then the final product of trypanothione. It also catalyzes the reverse reaction as well, albeit at a much lower rate. Under conditions found to be the optimum for both the forward and backwards reactions, trypanothione synthase from trypanosoma cruzi was found to have an amidase activity that was only about 1% of the forwards synthetase activity. This low activity can be explained by the blocking of the catalytic Cys in the amidase active site in order for the protein to properly fold. In parasitic kinetoplastids trypanothione synthase activity is key to survival. Due to the need for trypanothione in order to defend against oxidative stresses, and maintain thiol and ribonucleotide metabolism. It was observed that induced knockout of trypanothione synthase through RNA interference caused a reduced growth rate of twofold among trypanosoma brucei due to the immediate disruption of flux through thiol redox. In other similar experiments which observed cell death after knocking out trypanothione synthase, it was shown that after two hours of being exposed to hydrogen peroxide in order to mimic the oxidant attack of phagocytes, the cells which did not contain working trypanothione synthase had a much higher death rate than wild type T. brucei.
Sources: en.wikipedia.org
== History == Electron-capture dissociation was developed by Roman Zubarev and Neil Kelleher while in Fred McLafferty's lab at Cornell University. Irradiation of melittin 4+ ions and ubiquitin 10+ ions (trapped in FT-MS cell) by laser pulses not only resulted in peculiar c', z fragmentation but also charge reduction. It was suggested that if FT cell is modified to trap cations and electrons simultaneously, secondary electrons emitted by UV photons increases the charge reduction effect and c′, z• fragmentation. Replacing UV laser with EI source led to the development of this new technique.
== Academic career == Following his Ph.D. degree research into the pharmacokinetics of amphetamines, he took up a postdoctoral research appointment in the laboratory of Sidney Riegelman, School of Pharmacy, University of California, San Francisco (1965-1967), studying the pharmacokinetics of aspirin, and then took up a faculty position there (1967–75). While at UCSF. Rowland became a member of the joint Pharmacy-Medicine NIGMS funded program in Clinical Pharmacology, and moved his research from a prevailing descriptive approach to a more mechanistic, physiologically-based one, including the clearance concept that helped lay the foundations of modern pharmacokinetics. Together with Riegelman and Leslie Benet he founded the Journal of Pharmacokinetics and Biopharmaceutics (1973) (renamed Journal of Pharmacokinetics and Pharmacodynamics, 2001), and was a senior editor of it until 2007. In 1975 Rowland returned to the United Kingdom to take up a position of Professor of Pharmacy, University of Manchester where he extended his research on physiologically based pharmacokinetics including development of an in silico method for predicting tissue distribution of drugs based on tissue composition and physicochemical properties. In 1983 he founded Medeval, undertaking early stage clinical evaluation of new medicines under development. Together with Brian Houston and Leon Aarons he established the Centre for Applied Pharmacokinetic Research (1996). He has promoted the application of microdosing in clinical drug development.
== Overdose == There is limited experience with overdose of suvorexant. Suvorexant has been assessed in single doses of as high as 240 mg in clinical studies. The medication dose-dependently produces somnolence. High doses of suvorexant may also cause sleep-onset paralysis in some individuals (2% incidence at doses of 40–240 mg). Treatment of suvorexant overdose is based on symptoms and is supportive. Gastric lavage may be used where appropriate whereas the value of dialysis has not been determined. Because suvorexant has high plasma protein binding, hemodialysis is not expected to enhance elimination of suvorexant.
Sources: en.wikipedia.org
Aspartic acid (symbol Asp or D; known as aspartate in its anionic form), is an α-amino acid that is used in the biosynthesis of proteins. The L-isomer of aspartic acid is one of the 22 proteinogenic amino acids, i.e., the building blocks of proteins. D-aspartic acid is one of two D-amino acids commonly found in mammals. Apart from a few rare exceptions, D-aspartic acid is not used for protein synthesis but is incorporated into some peptides and plays a role as a neurotransmitter/neuromodulator. Like all other amino acids, aspartic acid contains an amino group and a carboxylic acid. Its α-amino group is in the protonated –NH+3 form under physiological conditions, while its α-carboxylic acid group is deprotonated −COO− under physiological conditions. Aspartic acid has an acidic side chain (CH2COOH) which reacts with other amino acids, enzymes and proteins in the body. Under physiological conditions (pH 7.4) in proteins the side chain usually occurs as the negatively charged aspartate form, −COO−. It is a non-essential amino acid in humans, meaning the body can synthesize it as needed. It is encoded by the codons GAU and GAC. In proteins aspartate sidechains are often hydrogen bonded to form asx turns or asx motifs, which frequently occur at the N-termini of alpha helices. Aspartic acid, like glutamic acid, is classified as an acidic amino acid, with a pKa of 3.9; however, in a peptide this is highly dependent on the local environment, and could be as high as 14. The one-letter code D for aspartate was assigned arbitrarily, with the proposed mnemonic asparDic acid.
Coalition members included Argentina, Australia, Bahrain, Bangladesh, Belgium, Canada, Czechoslovakia, Denmark, Egypt, France, Germany, Greece, Honduras, Hungary, Italy, Japan, Kuwait, Luxembourg, Morocco, the Netherlands, New Zealand, Niger, Norway, Oman, Pakistan, the Philippines, Poland, Portugal, Qatar, Romania, Saudi Arabia, Senegal, Sierra Leone, Singapore, South Korea, Spain, Sweden, Syria, Turkey, the United Arab Emirates, the United Kingdom and the United States. The United States had 700,000 troops. Germany and Japan provided financial assistance and donated military hardware, although they did not send direct military assistance. This later became known as checkbook diplomacy.
=== Uptake === Tau protein has been found in the extracellular environment including Cerebrospinal fluid (CSF) and Interstitial fluid (ISF) under physiological and pathological conditions. Low-density lipoprotein receptor-related protein 1 (LRP1) has been shown as the receptor for Tau internalization into cells. However, studying Tau uptake in human neurons revealed that physiological Tau monomers mainly use LRP1 for internalization, while the uptake of pathological Tau aggregates depend on heparan sulfate proteoglycans.
== External links == An Extremely Detailed Map of the 2024 Election from The New York Times "Misinformation Dashboard: Election 2024. A tool tracking the topics and tactics of 2024 election misinformation". News Literacy Project. 2024. Retrieved September 30, 2024. Dovere, Edward-Isaac (November 6, 2024). "Where Harris' campaign went wrong". CNN. Retrieved November 7, 2024. "The Choice 2024: Harris vs. Trump". Frontline. Season 43. Episode 2. September 24, 2024. PBS. WGBH. Retrieved November 28, 2024. "The VP Choice: Vance vs. Walz". Frontline. Season 43. Episode 3. October 8, 2024. PBS. WGBH. Retrieved November 28, 2024.
Sources: en.wikipedia.org
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.
Very few controlled human studies focus on the seven-residue sequence itself. Most clinical data concern the full-length protein in cardiac or ophthalmic settings. Conclusions drawn for one form should not be assumed to transfer to the other.
Detection normally relies on reversed-phase liquid chromatography paired with mass spectrometry. Chromatographic retention time establishes the expected elution window, and the mass spectrum confirms the molecular ion. Immunoassays exist but can cross-react with related peptides.
Desiccated storage at −20 °C is conventional, with −80 °C for extended periods. Vials should be warmed to room temperature before opening to prevent condensation on the powder.